{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:02:51Z","timestamp":1787162571268,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ygyno.2017.10.034","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T03:16:19Z","timestamp":1522206979000},"page":"84-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Disparities in genetics assessment for women with ovarian cancer: Can we do better?"],"prefix":"10.1016","volume":"149","author":[{"given":"Erica","family":"Manrriquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn S.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie M.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-may","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2017.10.034_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.ygyno.2017.10.034_bb0010","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.10.034_bb0015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ygyno.2005.10.029","article-title":"The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer","volume":"101","author":"Malander","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.10.034_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.10.034_bb0025","unstructured":"NCCN clinical practice guidelines in oncology: genetic\/familial high-risk assessment: breast and ovarian. January 2017."},{"issue":"1","key":"10.1016\/j.ygyno.2017.10.034_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/pgp.0b013e31814b191f","article-title":"Serous carcinogenesis in the fallopian tube: a descriptive classification","volume":"27","author":"Jarboe","year":"2008","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2017.10.034_bb0035","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.10.034_bb0040","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"15","key":"10.1016\/j.ygyno.2017.10.034_bb0045","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2017.10.034_bb0050","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2017.10.034_bb0055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2015.04.029","article-title":"Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals","volume":"138","author":"Febbraro","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2017.10.034_bb0060","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/AOG.0b013e3181da08d7","article-title":"Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities","volume":"115","author":"Meyer","year":"2010","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.10.034_bb0065","series-title":"R: A Language and Environment for Statistical Computing [Internet]","author":"R Core Team","year":"2015"},{"issue":"1","key":"10.1016\/j.ygyno.2017.10.034_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2017.10.034_bb0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-015-3374-7","article-title":"Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer","volume":"151","author":"Cragun","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"16","key":"10.1016\/j.ygyno.2017.10.034_bb0080","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/jama.287.16.2106","article-title":"Survival of blacks and whites after a cancer diagnosis","volume":"287","author":"Bach","year":"2002","journal-title":"JAMA"},{"issue":"36","key":"10.1016\/j.ygyno.2017.10.034_bb0085","doi-asserted-by":"crossref","first-page":"9079","DOI":"10.1200\/JCO.2004.00.1297","article-title":"Insurance status and the use for guideline therapy in the treatment of selected cancers","volume":"23","author":"Harlan","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.10.034_bb0090","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/AOG.0b013e31823d4006","article-title":"Disparities in the allocation of treatment in advanced ovarian cancer: are there certain patient characteristics associated with nonstandard therapy?","volume":"119","author":"Chase","year":"2012","journal-title":"Obstet. Gynecol."},{"issue":"11","key":"10.1016\/j.ygyno.2017.10.034_bb0095","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/jnci\/djt065","article-title":"Disparities in ovarian cancer care quality and survival according to race and socioeconomic status","volume":"105","author":"Bristow","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ygyno.2017.10.034_bb0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.11.025","article-title":"Have racial disparities in ovarian cancer increased over time? An analysis of SEER data","volume":"125","author":"Terplan","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2017.10.034_bb0105","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer","volume":"32","author":"Schwartz","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2017.10.034_bb0110","doi-asserted-by":"crossref","first-page":"690","DOI":"10.12968\/bjon.2016.25.12.690","article-title":"The integration of BRCA testing into oncology clinics","volume":"25","author":"Percival","year":"2016","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ygyno.2017.10.034_bb0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.10.034_bb0120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2017.01.030","article-title":"Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics","volume":"145","author":"Kentwell","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2017.10.034_bb0125","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/IGC.0000000000000148","article-title":"Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system","volume":"24","author":"Petzel","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2017.10.034_bb0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10897-013-9664-5","article-title":"The value of a genetic counselor: improving identification of cancer genetic counseling patients with chart review","volume":"23","author":"Eichmeyer","year":"2014","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ygyno.2017.10.034_bb0135","series-title":"Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care (with CD)","first-page":"432","author":"Institute of Medicine","year":"2003"},{"issue":"6","key":"10.1016\/j.ygyno.2017.10.034_bb0140","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0277-9536(99)00338-X","article-title":"The effect of patient race and socio-economic status on physicians' perceptions of patients","volume":"50","author":"Van Ryn","year":"2000","journal-title":"Soc. Sci. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2017.10.034_bb0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1037\/hea0000177","article-title":"Effects of racial and ethnic group and health literacy on responses to genomic risk information in a medically underserved population","volume":"34","author":"Kaphingst","year":"2015","journal-title":"Health Psychol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.10.034_bb0150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1055-9965.361.13.3","article-title":"The association between race and attitudes about predictive genetic testing","volume":"13","author":"Peters","year":"2004","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"2","key":"10.1016\/j.ygyno.2017.10.034_bb0155","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-015-3312-8","article-title":"The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer","volume":"150","author":"Villarreal-Garza","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"9","key":"10.1016\/j.ygyno.2017.10.034_bb0160","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/ijc.30633","article-title":"BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer","volume":"140","author":"Shi","year":"2017","journal-title":"Int. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817314555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817314555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T01:05:50Z","timestamp":1660698350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817314555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0090825817314555"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.10.034","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disparities in genetics assessment for women with ovarian cancer: Can we do better?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}